Prestige Consumer Healthcare (NYSE:PBH) Reaches New 52-Week High – Should You Buy?

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $82.56 and last traded at $82.27, with a volume of 8579 shares changing hands. The stock had previously closed at $81.75.

Wall Street Analyst Weigh In

PBH has been the subject of a number of recent research reports. DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Performance

The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock’s 50-day simple moving average is $72.84 and its two-hundred day simple moving average is $70.00. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.30 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently bought and sold shares of PBH. Ariel Investments LLC lifted its stake in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after buying an additional 274,212 shares during the period. Victory Capital Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after acquiring an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Prestige Consumer Healthcare by 19.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after purchasing an additional 255,045 shares in the last quarter. Congress Asset Management Co. increased its position in shares of Prestige Consumer Healthcare by 7.8% during the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after purchasing an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp acquired a new position in shares of Prestige Consumer Healthcare in the third quarter valued at $41,785,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.